Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Pharmaceutical Care in Depressed Outpatients (depression)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Federal University of São Paulo.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Ana Regina Noto, Federal University of São Paulo
ClinicalTrials.gov Identifier:
NCT01571973
First received: April 3, 2012
Last updated: April 4, 2012
Last verified: June 2011

April 3, 2012
April 4, 2012
March 2010
March 2012   (final data collection date for primary outcome measure)
depression level [ Time Frame: six months ] [ Designated as safety issue: No ]
evaluation depression level by Beck scale
Same as current
Complete list of historical versions of study NCT01571973 on ClinicalTrials.gov Archive Site
  • anxiety level [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    evaluation anxiety level by Beck scale.
  • compliance [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    evaluation antidepressive treatment compliance by Morisky scale
Same as current
Not Provided
Not Provided
 
Evaluation of Pharmaceutical Care in Depressed Outpatients
EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL CARE (DÁDER PROGRAM) IN DEPRESSED OUTPATIENTS TREATED WITH PSYCHOTROPIC

The study examines whether pharmacotherapeutic follow-up improves outcomes of treatment of depressed outpatients.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Depression
Procedure: pharmacotherapeutic follow-up
health education adjustment of dose improve compliance replacement of medication
  • No Intervention: control group
    outpatients receiving usual care
  • Experimental: intervention group
    outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
    Intervention: Procedure: pharmacotherapeutic follow-up
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
May 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • women between 18 and 65 years, with diagnostic hypothesis of depression at the beginning of treatment or change in treatment unless 2 months (dosage or substance)

Exclusion Criteria:

  • record of dependence on psychoactive substances, diagnosed schizophrenia,
  • low education (illiterate) or cognitive impairment evident that compromise the completion of research instruments
Female
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01571973
SPPsicobio1Lu
Yes
Ana Regina Noto, Federal University of São Paulo
Federal University of São Paulo
Not Provided
Not Provided
Federal University of São Paulo
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP